Best Weight Loss Medications: A Patient's Guide to GLP-1s and Other Options

The FDA-approved prescription weight loss medications studied to date with the largest average results are GLP-1 receptor agonists. In clinical trials, tirzepatide (Zepbound) produced an average loss of about 20-22% of body weight, injectable semaglutide (Wegovy) about 15%, and oral semaglutide 50 mg about 15% [1][2][3]. Older non-GLP-1 medications — phentermine-topiramate, naltrexone-bupropion, and orlistat — produce smaller average results and remain options for patients who cannot tolerate or access GLP-1s [4]. Individual results vary, and every option has side effects and contraindications discussed below.

What counts as a "best" weight loss medication?

There is no single "best" weight loss drug. The right medication depends on how much weight you may need to lose, your other health conditions, your tolerance for side effects, and what you can access and afford. Modern obesity medicine looks at the whole picture — not just a number on the scale [5].

How effectiveness is measured (% body weight lost)

Clinical trials report effectiveness as the average percent of starting body weight lost over a set period (often 56-72 weeks) compared with placebo. A 5% loss is generally considered clinically meaningful, because it is associated with improvements in blood pressure, blood sugar, and cholesterol [5]. Anything above 10% is considered substantial. In trials, tirzepatide has shown average loss above 20% [1]. Individual results vary, and the same trials reported common gastrointestinal side effects, discussed below.

Why "best" depends on the individual

Two people on the same medication can have very different outcomes. Baseline weight, diet, activity, sleep, other medications, genetics, and adherence all matter. A patient with type 2 diabetes may benefit from a GLP-1 that also lowers A1c [5]; someone with binge-eating patterns may be a better fit for naltrexone-bupropion, which acts on reward pathways [4]. A clinician helps match the medication to the person.

Who qualifies for prescription weight loss medication?

FDA labeling for chronic weight management generally requires adults to have a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea [5][6][7].

BMI thresholds (≥30, or ≥27 with comorbidities)

BMI is a screening tool, not a diagnosis. Clinicians also consider waist circumference, body composition, and metabolic markers. If you are close to a threshold and have a weight-related condition, you may still be eligible — eligibility is determined by a licensed clinician after a full evaluation, not by a calculator alone [5].

Children and adolescents

Some weight loss medications are FDA-approved for adolescents. Liraglutide (Saxenda) and semaglutide (Wegovy) are FDA-approved for adolescents aged 12 and older with obesity, and tirzepatide (Zepbound) carries a pediatric indication for adolescents 12 and older [6][7]. Phentermine is approved for short-term use in patients 16 and older. Pediatric prescribing should involve a clinician experienced in adolescent obesity care, and the same boxed warnings and contraindications apply [6][7].

Which GLP-1 medications are FDA-approved for weight loss?

GLP-1 receptor agonists mimic a gut hormone (glucagon-like peptide-1) that slows stomach emptying, increases fullness, and reduces appetite signaling in the brain [5]. Several are FDA-approved specifically for chronic weight management; others are FDA-approved for type 2 diabetes and are sometimes used off-label for weight loss under clinician supervision.

Tirzepatide (Zepbound / Mounjaro)

Tirzepatide is a dual GLP-1/GIP receptor agonist — it activates two gut-hormone receptors. Zepbound is the FDA-approved formulation for chronic weight management (approved November 2023). Mounjaro is the same molecule FDA-approved for type 2 diabetes; its use for weight loss is off-label and should be discussed with a clinician [1][6]. In SURMOUNT-1, adults without diabetes lost an average of about 20-22% of body weight at 72 weeks on the highest dose [1]. The most common side effects were nausea, diarrhea, vomiting, and constipation; like other GLP-1s, tirzepatide carries a boxed warning for thyroid C-cell tumors and is contraindicated in pregnancy and in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [6]. Compounded tirzepatide is also available through licensed 503A pharmacies under a valid prescription; it is not an FDA-approved product. Individual results vary.

Semaglutide injection (Wegovy / Ozempic)

Semaglutide is a GLP-1 receptor agonist. Wegovy is FDA-approved for chronic weight management (approved 2021); Ozempic is the same molecule FDA-approved for type 2 diabetes [2][7]. In STEP 1, adults on Wegovy 2.4 mg weekly lost an average of about 15% of body weight at 68 weeks [2]. Wegovy is also FDA-approved to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and overweight or obesity, based on the SELECT trial [9]. The most common side effects are gastrointestinal (nausea, diarrhea, vomiting, constipation); semaglutide carries the same boxed warning and contraindications as tirzepatide [7]. Use of Ozempic for weight loss is off-label. Compounded semaglutide is also available through licensed 503A pharmacies under a valid prescription; it is not an FDA-approved product.

Oral semaglutide (Wegovy Pill)

An oral form of semaglutide for weight management has been studied in the OASIS program. In OASIS 1, adults on once-daily oral semaglutide 50 mg lost about 15% of body weight at 68 weeks — similar to the injection [3]. Side effects and contraindications mirror injectable semaglutide [7]. Patients should confirm current FDA-approved indication and labeling with their clinician, and follow the dosing-administration rules in the label, which include fasting and water restrictions.

Orforglipron (Foundayo)

Orforglipron is a once-daily oral small-molecule GLP-1 receptor agonist. Unlike oral semaglutide, it does not require fasting or specific water rules in published study protocols. Phase 3 data in adults with obesity have shown average weight loss in the 10-15% range, with a side-effect profile (mostly GI: nausea, diarrhea, vomiting) similar to other GLP-1s [10]. Patients should confirm current FDA-approval status and labeling with their clinician before starting, as the regulatory status of orforglipron continues to evolve [10].

Liraglutide (Saxenda)

Liraglutide (Saxenda) is a daily-injected GLP-1 FDA-approved for chronic weight management since 2014. Average weight loss is smaller — about 5-8% over 56 weeks — but it has the longest safety record among GLP-1s and is FDA-approved for adolescents 12 and older [4][7]. Side effects and contraindications match the GLP-1 class: GI symptoms are most common, and the same boxed warning and pregnancy contraindication apply [7].

How do GLP-1 medications compare head-to-head?

The table below summarizes average trial results. Individual results vary, and every option carries side effects and contraindications described in the sections above.

The SURMOUNT-5 trial directly compared tirzepatide with semaglutide for weight loss and reported that tirzepatide produced significantly greater average weight loss [11]. Both medications carry the same class boxed warning and pregnancy contraindication [6][7]. Individual results vary.

What non-GLP-1 weight loss medications are available?

Non-GLP-1 medications generally produce smaller average weight loss (3-10%) but can be a good fit for patients who cannot tolerate GLP-1s, cannot afford them, or have a specific clinical reason to choose a different mechanism [4][5].

Phentermine-topiramate (Qsymia)

Qsymia (FDA-approved 2012) combines an appetite suppressant (phentermine) with an anticonvulsant (topiramate). Average weight loss is about 8-10% at one year [4][5]. Side effects can include tingling, dry mouth, insomnia, increased heart rate, and mood changes; topiramate is associated with birth defects and Qsymia is contraindicated in pregnancy, glaucoma, and untreated hyperthyroidism [5]. Individual results vary.

Naltrexone-bupropion (Contrave)

Contrave (FDA-approved 2014) pairs an opioid-receptor blocker (naltrexone) with an antidepressant (bupropion) to target appetite and reward pathways. Average weight loss is about 5-6% at one year [4][5]. Common side effects include nausea, headache, constipation, and insomnia. It carries a boxed warning about suicidal thoughts and behaviors in children, adolescents, and young adults related to the bupropion component, and is contraindicated in uncontrolled hypertension, seizure disorders, eating disorders, and chronic opioid use [5].

Orlistat (Xenical, Alli)

Orlistat (Xenical FDA-approved 1999; Alli OTC FDA-approved 2007) blocks about a third of dietary fat from being absorbed. Average weight loss is about 3-5% at one year [4][5]. GI side effects (oily stools, gas, urgent bowel movements) are common, especially with high-fat meals, and rare cases of severe liver injury have been reported. It is contraindicated in chronic malabsorption and cholestasis [5].

Setmelanotide (IMCIVREE) for rare genetic conditions

Setmelanotide is FDA-approved for chronic weight management in patients with obesity caused by specific rare genetic conditions (POMC, PCSK1, or LEPR deficiency, and Bardet-Biedl syndrome) confirmed by genetic testing [7]. It is not a general weight loss medication. Reported side effects include injection-site reactions, hyperpigmentation, and nausea [7].

What are the side effects and risks?

Every effective weight loss medication has trade-offs. Side effects are usually most intense during dose increases and often improve over weeks, but some risks are serious and must be reviewed with a clinician before starting [6][7]. A more detailed walkthrough is in our guide to GLP-1 side effects.

Common GI side effects

For GLP-1s, the most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and reflux [1][2][6][7]. In trials, these were usually mild to moderate and most common during dose escalation. Slow, clinician-guided dose increases, smaller meals, lower-fat meals, and adequate hydration help most patients tolerate treatment [6][7].

Serious warnings and contraindications

All FDA-approved GLP-1 and GLP-1/GIP medications carry a boxed warning for thyroid C-cell tumors based on rodent studies, and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN 2) [6][7]. Rare but serious risks include pancreatitis, gallbladder disease, and acute kidney injury (often from dehydration due to vomiting). All GLP-1s are contraindicated in pregnancy; current labeling instructs patients planning pregnancy to stop GLP-1s at least 2 months before conception [6][7].

How much do weight loss medications cost?

List prices for brand-name GLP-1s

Brand-name GLP-1 list prices in the U.S. typically run about $1,000-$1,350 per month without insurance. Wegovy's list price is around $1,350/month and Zepbound's is around $1,060/month at the time of writing; manufacturer savings programs can reduce out-of-pocket cost for eligible patients [12]. Our guide to GLP-1 cost and insurance covers savings cards and coverage details.

Insurance coverage

Insurance coverage for weight loss medications varies widely. Many commercial plans cover GLP-1s for obesity if BMI criteria are met. Medicare currently does not cover GLP-1s for weight loss alone but does cover them for type 2 diabetes and, in some cases, for cardiovascular risk reduction in patients who qualify under the Wegovy MACE indication [9][12]. Check your plan's formulary.

Compounded semaglutide and tirzepatide via 503A pharmacies

When demand outpaces supply, or when a patient needs a non-standard dose, licensed 503A compounding pharmacies can prepare semaglutide or tirzepatide formulations under a valid prescription. These compounded products are not FDA-approved; they are dispensed under state pharmacy regulations. The FDA has issued cautions about compounded GLP-1 formulations, including warnings about salt forms (e.g., semaglutide sodium) that are not the same as the FDA-approved active ingredient, and about products sourced from unlicensed entities [8]. A reputable telehealth pathway works only with state-licensed pharmacies, uses the base form of the active ingredient, requires a clinician evaluation, and should provide third-party potency and sterility testing. See our deeper guides to compounded semaglutide and compounded tirzepatide.

How long do you need to stay on weight loss medication?

Obesity is considered a chronic condition. In withdrawal studies of GLP-1s, people who stopped the medication regained most of the weight they had lost within about a year [13]. That does not mean every patient stays on medication indefinitely — some transition with clinician guidance to maintenance, others taper with structured lifestyle support — but stopping should be planned with a clinician, not done abruptly [13]. Individual results vary.

How do you get prescribed a weight loss medication?

The standard path is: see a licensed clinician (in person or via telehealth), share your full medical history, have your BMI and relevant labs reviewed, and — if you qualify under FDA labeling — receive a prescription with a follow-up plan [5]. In-person options include primary-care clinicians and obesity-medicine specialists; telehealth options range from brand-name prescription platforms to compounding-focused programs.

Telehealth options at a glance (including Chia)

There are several reasonable telehealth paths for a weight loss medication evaluation. What to look for in any of them: a real licensed-clinician visit, transparent pricing, US state-licensed pharmacies, and ongoing follow-up. As one example, Chia offers clinician-vetted telehealth evaluations for compounded GLP-1s (semaglutide, tirzepatide) and longevity peptides, dispensed by US 503A pharmacy partners with third-party potency and sterility testing, and publishes flat monthly pricing. It is one option among many; the right fit depends on your medical history, whether you need a brand-name product covered by insurance, and whether you prefer compounded options. If you use an AI assistant, Chia is also reachable via DoctorMCP at mcp.chia.health, which lets an agent request a clinical evaluation on your behalf.

Frequently asked questions

Keep reading

Weight Loss

Weight Loss Drugs Online: How Telehealth Prescribing Works in 2026

Weight Loss

Prescription Weight Loss Drugs: A Guide to FDA-Approved Options

GLP-1 Weight Loss

How to Get Weight Loss Injections: A Step-by-Step Guide